Aminohexylgeldanamycin

Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities[1].

Product Specifications

CAS Number

[485395-71-9]

Product Name Alternative

AHGDM

UNSPSC

12352203

Target

ADC Payload; HSP

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aminohexylgeldanamycin.html

Purity

99.82

Solubility

DMSO : 110 mg/mL (ultrasonic)

Smiles

O=C(C(NCCCCCCN)=C1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(C)\C2=O)C=C(N2)C1=O

Molecular Formula

C34H52N4O8

Molecular Weight

644.80

References & Citations

[1]Greish K, et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. J Control Release. 2011;151 (3) :263-270.|[2]Larson N, et al. HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res. 2010;27 (12) :2683-2693.